Recombinant bpi proteins, uses of bpi proteins, and methods of preparing same

Proteines bpi recombinees, utilisation et procedes de preparation de ces proteines

Abstract

Cette invention concerne une composition comprenant une protéine BPI et un composé anionique. Ladite composition ne présente (1) aucune activité bactéricide mais (2) une activité de neutralisation des endotoxines. En outre, cette invention décrit des procédés d'utilisation des protéines BPI.
The present invention provides a composition comprising a BPI Protein and an anionic compound which composition exhibits (1) no bactericidal activity and (2) endotoxin neutralizing activity. Also, this invention provides methods for using BPI Proteins.

Claims

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (0)

    Publication numberPublication dateAssigneeTitle

NO-Patent Citations (7)

    Title
    Journal of Biological Chemistry, Volume 264, No. 18, issued 25 June 1989, TOBIAS et al., "Identification of a Lipid A Binding site in the Acute Phase Reactant Lipopolysaccharide Binding Protein", pages 10867-10871, entire article.
    Science, Volume 249, issued 21 September 1990, SCHUMANN et al., "Structure and Function of Lipopolysaccharide Binding Protein", pages 1429-1431, see entire article.
    Science, Volume 249, issued 21 September 1990, WRIGHT et al., "CD14, a Receptor for Complexes of Lipopolysaccharide (LPS) and LPS Binding Protein", pages 1431-1433, see entire article.
    See also references of EP 0544832A4
    The Journal of Biological Chemistry, Volume 262, No. 31, issued 05 November 1987, OOI et al., "A 25kDa NH2-terminal Fragment carries all the Antibacterial Activities of the Human Neutrophil 60-kDa Bactericidal/Permeability-increasing Protein", pages 14891-14894, see entire article.
    The Journal of Biological Chemistry, Volume 264, No. 16, issued 05 June 1989, GRAY et al., "Cloning of the cDNA of a Human Neutrophil Bactericidal Protein", pages 9505-9509, see pages 9505 & 9507.
    The Journal of Immunology, Volume 144, No. 2, issued 15 January 1990, MARRA et al., "Bactericidal/Permeability-Increasing protein has Endotoxin-Neutralizing Activity", pages 662-666, see entire article.

Cited By (107)

    Publication numberPublication dateAssigneeTitle
    US-6107280-AAugust 22, 2000Xoma CorporationAntithrombotic materials and methods
    US-6767893-B2July 27, 2004Xoma CorporationMethod of treating conditions associated with intestinal ischemia/reperfusion
    US-5952302-ASeptember 14, 1999Xoma CorporationHuman therapeutic uses of BPI protein products
    US-5578572-ANovember 26, 1996Xoma CorporationAnti-gram-positive bacterial methods and materials
    US-6440936-B2August 27, 2002Xoma CorporationAnti-protozoan methods and materials
    US-5888977-AMarch 30, 1999Giroir; Brett P., Scannon; Patrick J.Therapeutic uses of BPI protein products for human meningococcemia
    US-5523288-AJune 04, 1996Xoma CorporationMethod of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (BPI) protein product and antibiotic
    US-5945399-AAugust 31, 1999Xoma CorporationTherapeutic uses of BPI protein products in humans with hemorrhage due to trauma
    US-5990086-ANovember 23, 1999Xoma CorporationTherapeutic uses of BPI protein products for human meningococcemia
    US-6274348-B1August 14, 2001Xoma CorporationMethods for the preparation of positively charged proteins
    US-5783561-AJuly 21, 1998Xoma CorporationAnti-gram-positive bacterial methods and materials
    US-5639727-AJune 17, 1997Xoma CorporationTherapeutic uses of bactericidal/permeability increasing protein products
    US-6427681-B1August 06, 2002Aradigm CorporationMethod of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
    US-6271203-B1August 07, 2001Xoma CorporationAnti-protozoan methods and materials
    US-5753620-AMay 19, 1998Xoma CorporationHuman therapeutic uses of BPI protein products
    US-6268345-B1July 31, 2001Xoma CorporationBactericidal/permeability-increasing protein (BPI) compositions
    US-5990082-ANovember 23, 1999Xoma CorporationUses of lipopolysaccharide binding protein
    US-5932544-AAugust 03, 1999Xoma CorporationBactericidal/permeability-increasing protein (BPI) compositions
    EP-0760849-A4December 02, 1996Incyte Pharma IncRecombinant bpi-based and lbp-based proteins, nucleic acid molecules encoding same, methods of producing same, and uses thereof
    US-9540426-B2January 10, 2017Bristol-Myers Squibb CompanyMammalian cell culture processes for protein production
    US-6583116-B1June 24, 2003Xoma CorporationAnti-chlamydial methods and materials
    US-7021309-B2April 04, 2006Aradigm CorporationMethod of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
    US-6191112-B1February 20, 2001Xoma CorporationHuman therapeutic uses of BPI protein products
    WO-0136478-A3October 31, 2002Hyseq Inc, David G Ballinger, Julio J Mulero, Xiaohong Qian, Nancy K Mize, Dana A Haley, Bryan J BoyleMethods and compositions relating to bactericidal/permeability increasing factor-like polypeptides and polynucleotides
    US-6647987-B2November 18, 2003Aradigm CorporationInsulin delivery enhanced by coached breathing
    US-5420019-AMay 30, 1995Xoma CorporationStable bactericidal/permeability-increasing protein muteins
    US-6759203-B1July 06, 2004Xoma CorporationMethod for quantifying BPI in body fluids
    WO-2009026155-A2February 26, 2009The United States Of America, As Represented By The Secretary Of AgricultureAntimicrobial activity of bovine bactericidal/permeability-increasing protein (bpi) - derived peptides against gram-negative bacterial mastitis isolates
    US-5821064-AOctober 13, 1998Xoma CorporationMethod of screening for an active inflammatory state by determining the concentration of extracellular BPI
    US-5763567-AJune 09, 1998Xoma CorporationBiologically active peptides from funcional domains of bactericidal/permeability-increasing protein and uses thereof
    WO-9323540-A2November 25, 1993Xoma CorporationImproved methods for the preparation of endotoxin-binding proteins
    US-5837678-ANovember 17, 1998Xoma CorporationTherapeutic uses of bactericidal/permeability increasing protein products
    WO-2009026155-A3April 30, 2009Douglas D Bannerman, Annapoorani Chockalingam, Us Agriculture, Dante S ZarlengaActivité antimicrobienne de peptides issus d'une protéine bovine bactéricide augmentant la perméabilité (bpi) à l'encontre d'isolats gram-négatifs de mastite bactérienne
    US-6482796-B2November 19, 2002Xoma CorporationTherapeutic uses of N-terminal BPI protein products in ANCA-positive patients
    US-6087126-AJuly 11, 2000Xoma CorporationBactericidal/permeability-increasing protein (BPI) deletion analogs
    EP-0938585-A4October 13, 2004Ass Cape Cod IncDetection et quantification d'une endotoxine par polarisation de fluorescence
    US-6051553-AApril 18, 2000Xoma CorporationMethod for potentiating BPI protein product bactericidal activity by administration of LBP protein products
    WO-9418323-A1August 18, 1994Xoma CorporationStable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same
    US-5955427-ASeptember 21, 1999Xoma CorporationPharmaceutical composition
    US-6242418-B1June 05, 2001Xoma Corporation, The Board Of Regents, The University Of Texas SystemTherapeutic uses of BPI protein products for human meningococcemia
    WO-9323434-A3January 06, 1994Xoma CorpProteines de fusion de l'immunoglobuline bactericides augmentant la permeabilite
    US-5780429-AJuly 14, 1998Marine Biological LaboratoryAnti-LPS factor from horseshoe crabs and methods of use
    US-5970973-AOctober 26, 1999Aradigm CorporationMethod of delivering insulin lispro
    WO-9323540-A3January 20, 1994Xoma CorpImproved methods for the preparation of endotoxin-binding proteins
    US-6066620-AMay 23, 2000Xoma CorporationPharmaceutical compositions of bactericidal/permeability increasing protein (BPI)
    US-6596691-B2July 22, 2003Xoma CorporationTherapeutic uses of BPI protein products for human meningococcemia
    US-6250298-B1June 26, 2001Aradigm CorporationMethod of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
    US-6676936-B1January 13, 2004The United States Of America As Represented By The Department Of Health And Human Services.Chimeric and/or growth-restricted flaviviruses
    US-5756464-AMay 26, 1998Xoma CorporationTherapeutic uses of BPI protein products in humans with hemmorhage due to trauma
    US-5652332-AJuly 29, 1997XomaBiologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
    EP-0760849-A1March 12, 1997Incyte Pharmaceuticals, Inc.Recombinant bpi-based and lbp-based proteins, nucleic acid molecules encoding same, methods of producing same, and uses thereof
    US-6085753-AJuly 11, 2000Aradigm CorporationInsulin delivery enhanced by coached breathing
    US-6431167-B1August 13, 2002Aradigm CorporationMethod of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
    US-5674834-AOctober 07, 1997Xoma CorporationStable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same
    US-5858974-AJanuary 12, 1999Xoma CorporationAnti-fungal peptides
    US-6376462-B1April 23, 2002Xoma CorporationLipopolysaccharide binding protein derivatives
    US-5873358-AFebruary 23, 1999Aradigm CorporationMethod of maintaining a diabetic patient's blood glucose level in a desired range
    US-6098615-AAugust 08, 2000Aradigm CorporationMethod of reproducibly effecting a patient's glucose level
    US-6140306-AOctober 31, 2000Xoma CorporationMethod of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (BPI) protein product and antibiotic
    US-6306824-B1October 23, 2001Xoma CorporationUses of lipopolysaccharide binding protein
    US-6384188-B1May 07, 2002Dana-Farber Cancer Institute, Inc.Lipopolysaccharide-binding and neutralizing peptides
    US-6408854-B1June 25, 2002Aradigm CorporationInsulin delivery enhanced by coached breathing
    US-5827816-AOctober 27, 1998Xoma CorporationStable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same
    US-6599880-B1July 29, 2003Xoma CorporationBactericidal/permeability-increasing protein (BPI) deletion analogs
    US-6057293-AMay 02, 2000Xoma CorporationBactericidal/permeability-increasing protein (BPI) compositions
    US-5915378-AJune 29, 1999Aradigm CorporationCreating an aerosolized formulation of insulin
    US-5627153-AMay 06, 1997Xoma CorporationAnti-fungal methods and materials
    US-6431166-B2August 13, 2002Aradigm CorporationMethod of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
    US-6214789-B1April 10, 2001Xoma CorporationTreatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
    US-6013631-AJanuary 11, 2000Xoma CorporationBactericidal/permeability-increasing protein (BPI) deletion analogs
    WO-9500641-A1January 05, 1995Xoma CorporationLipopolysaccharide binding protein derivatives
    US-6265187-B1July 24, 2001Incyte Pharmaceuticals, Inc.Recombinant endotoxin-neutralizing proteins
    US-5494896-AFebruary 27, 1996Xoma CorporationMethod of treating conditions associated with burn injuries
    US-5578568-ANovember 26, 1996Xoma CorporationMethod of treating conditions associated with intestinal ischemia/reperfusion
    US-6586400-B2July 01, 2003Xoma CorporationHuman therapeutic uses of BPI protein products
    WO-9420129-A1September 15, 1994Xoma CorporationTraitement de maladies mycobacteriennes par adminstration de produits proteiques bactericides/augmentant la permeabilite
    US-5888973-AMarch 30, 1999Xoma CorporationAnti-chlamydial uses of BPI protein products
    US-6620785-B2September 16, 2003Xoma CorporationTreatment of Mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
    US-6131567-AOctober 17, 2000Aradigm CorporationMethod of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
    US-5646114-AJuly 08, 1997Xoma CorporationAnti-protozoan methods
    US-5856438-AJanuary 05, 1999Xoma CorporationBiologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
    US-5741779-AApril 21, 1998Xoma CorporationAntithrombotic materials and methods
    US-5696090-ADecember 09, 1997Xoma CorporationPharmaceutical composition
    WO-9323434-A2November 25, 1993Xoma CorporationBpi-immunoglobulin fusion proteins
    US-6255284-B1July 03, 2001Xoma CorporationPharmaceutical composition
    WO-9510297-A1April 20, 1995Xoma CorporationProcede de traitement du fonctionnement reduit du systeme reticulo-endothelial
    US-6093573-AJuly 25, 2000Xoma, The Regents Of The University Of CaliforniaThree-dimensional structure of bactericidal/permeability-increasing protein (BPI)
    US-6384200-B1May 07, 2002Associates Of Cape Cod, Inc.Endotoxin binding and neutralizing protein and uses thereof
    US-5854214-ADecember 29, 1998Xoma CorporationTherapeutic uses of bactericidal/permeability increasing protein products
    US-6162788-ADecember 19, 2000Xoma CorporationUses of BPI protein products
    US-6024090-AFebruary 15, 2000Aradigm CorporationMethod of treating a diabetic patient by aerosolized administration of insulin lispro
    US-5643875-AJuly 01, 1997Friedmann; Nadav, Scannon; Patrick J., Van Deventer; Sander J. H., Von Der Mohlen; Marijke A. M., Wedel; NancyHuman therapeutic uses of bactericidal/permeability increasing (BPI) protein products
    US-5807818-ASeptember 15, 1998Xoma CorporationTherapeutic uses of bactericidal/permeability increasing protein (BPI) protein products
    US-6017881-AJanuary 25, 2000Xoma CorporationMethod of treating conditions associated with intestinal ischemia/reperfusion
    US-6054431-AApril 25, 2000Xoma CorporationAnti-gram-positive bacterial methods and materials
    US-6013629-AJanuary 11, 2000Xoma CorporationAnti-protozoan methods and materials
    US-5770561-AJune 23, 1998Xoma CorporationMethod for potentiating BPI protein product bactericidal activity by administration of LBP protein products
    US-6433140-B1August 13, 2002Xoma CorporationStable bactericidal permeability-increasing protein products and pharmaceutical compositions containing the same
    US-5888477-AMarch 30, 1999Aradigm CorporationUse of monomeric insulin as a means for improving the bioavailability of inhaled insulin
    US-5935930-AAugust 10, 1999Xoma CorporationAntithrombotic materials and methods
    WO-0136478-A2May 25, 2001Hyseq, Inc.Methodes et compositions se rapportant a des polypeptides et a des polynucleotides similaires au facteur bactericide augmentant la permeabilite
    US-6599881-B1July 29, 2003Xoma CorporationAntithrombotic materials and methods
    US-5731415-AMarch 24, 1998Xoma CorporationLipopolysaccharide binding protein derivatives
    US-6828418-B2December 07, 2004Xoma CorporationStable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same
    US-7490603-B2February 17, 2009Aradigm CorporationMethod of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
    EP-0938585-A1September 01, 1999Associates Of Cape Cod, Inc.Detection et quantification d'une endotoxine par polarisation de fluorescence